{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06036784",
            "orgStudyIdInfo": {
                "id": "MBX-1P2001"
            },
            "organization": {
                "fullName": "MBX Biosciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects",
            "officialTitle": "A Phase 1 Single and Multiple Ascending Dose and Drug Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics",
            "therapeuticArea": [
                "Other"
            ],
            "study": "safety-tolerability-pharmacokinetic-and-pharmacodynamic-study-of-mbx-in-healthy-subjects"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-17",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-17",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-28",
            "studyFirstSubmitQcDate": "2023-09-11",
            "studyFirstPostDateStruct": {
                "date": "2023-09-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "MBX Biosciences",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "ProSciento, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers\n\nThis study includes 3 parts. Part A involves a single dose of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part B involves repeat doses of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part C involves the evaluation of rosuvastatin and acetaminophen pharmacokinetics in the presence and absence of MBX 1416."
        },
        "conditionsModule": {
            "conditions": [
                "Postbariatric Hypoglycemia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Double Blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 84,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "MBX 1416 (Part A)",
                    "type": "EXPERIMENTAL",
                    "description": "Single ascending subcutaneous (SC) doses",
                    "interventionNames": [
                        "Drug: MBX 1416 (Part A)"
                    ]
                },
                {
                    "label": "MBX 1416 (Part B)",
                    "type": "EXPERIMENTAL",
                    "description": "Repeated ascending subcutaneous (SC) doses",
                    "interventionNames": [
                        "Drug: MBX 1416 (Part B)"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "MBX 1416 (Part C)",
                    "type": "EXPERIMENTAL",
                    "description": "Single subcutaneous (SC) dose of MBX 1416, single dose of rosuvastatin and acetaminophen.",
                    "interventionNames": [
                        "Drug: MBX 1416 (Part C)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "MBX 1416 (Part A)",
                    "description": "Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg",
                    "armGroupLabels": [
                        "MBX 1416 (Part A)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "MBX 1416 (Part B)",
                    "description": "Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg",
                    "armGroupLabels": [
                        "MBX 1416 (Part B)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Single dose or repeated subcutaneous (SC) dose of placebo.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "MBX 1416 (Part C)",
                    "description": "Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.",
                    "armGroupLabels": [
                        "MBX 1416 (Part C)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with adverse events (AEs), Serious Adverse Events (SAEs)",
                    "timeFrame": "Baseline through Day 29 (Part A) or Day 45 (Part B) and Day 21 (Part C)"
                },
                {
                    "measure": "Maximum Plasma Concentration (Cmax)",
                    "timeFrame": "Baseline through Day 29 (Part A) or Day 45 (Part B) and Day 21 (Part C)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Part A/B/C Inclusion Criteria:\n\n1. Female and male adults, ages \u2265 18 and \u2264 65 years with a body mass index (BMI) \u2265 18 kg/m\u00b2 to \u2264 30.0 kg/m\u00b2 and fasting glucose \\< 100 mg/dL and HbA1c \\< 5.7%.\n2. Female subjects of childbearing potential (WOCBP) and male subjects must use highly effective contraception.\n\nPart A/B/C Exclusion Criteria:\n\n1. Pregnant, lactating or intending to become pregnant during the study.\n2. Use of weight-lowering pharmacotherapy or participation in a clinical weight control study within the previous 3 months prior to the first dose of study drug.\n3. Presence of clinically significant ECG findings\n4. Subjects with a prior history of any serious adverse reaction, hypersensitivity or angioedema to GLP-1 receptor agonists, study drug or drug components.\n5. Abnormal laboratory results at Screening.\n6. History of renal disease or abnormal kidney function tests at Screening\n7. Presence of any clinically significant physical exam, ECG, or laboratory findings at screening.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pavla Bednarek, MD",
                    "role": "CONTACT",
                    "phone": "619-500-1836",
                    "email": "pavla.bednarek@prosciento.com"
                },
                {
                    "name": "Kirk Ways, MD, PhD",
                    "role": "CONTACT",
                    "phone": "619-849-5388",
                    "email": "kways@mbxbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "MBX Biosciences Investigational Site",
                    "status": "RECRUITING",
                    "city": "Chula Vista",
                    "state": "California",
                    "zip": "91911",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Carmen Flores",
                            "role": "CONTACT",
                            "phone": "619-755-8301",
                            "email": "carmen.flores@prosciento.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.64005,
                        "lon": -117.0842
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007003",
                    "term": "Hypoglycemia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10053",
                    "name": "Hypoglycemia",
                    "asFound": "Hypoglycemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M298",
                    "name": "Rosuvastatin Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M2340",
                    "name": "Acetaminophen",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Antipy",
                    "name": "Antipyretics"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}